| Record ID | harvard_bibliographic_metadata/ab.bib.13.20150123.full.mrc:433435075:1372 |
| Source | harvard_bibliographic_metadata |
| Download Link | /show-records/harvard_bibliographic_metadata/ab.bib.13.20150123.full.mrc:433435075:1372?format=raw |
LEADER: 01372cam a2200301 a 4500
001 013379215-3
005 20121016021144.0
006 m d f
008 090609s1997 mdu ob f000 0 eng c
035 0 $aocn379737812
035 $a(FDLP)ocn379737812
040 $aGPO$cGPO$dGPO
042 $apcc
043 $an-us---
074 $a0499-T-02 (online)
086 0 $aHE 20.4802:M 75
245 00 $aPoints to consider in the manufacture and testing of monoclonal antibody products for human use$h[electronic resource] .
260 $aRockville, MD :$bU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,$c[1997]
300 $a1 online resource (50 p.)
538 $aMode of access: Internet at the FDA web site. Address as of 6/9/09: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/OtherRecommendationsforManufacturers/UCM153182.pdf ; current access is available via PURL.
500 $aTitle from title screen (viewed on June 9, 2009).
500 $a"February 28, 1997".
504 $aIncludes bibliographical references (p. 49-50).
650 0 $aMonoclonal antibodies.
650 0 $aBiological products$xTesting$xGovernment policy$zUnited States.
710 2 $aCenter for Biologics Evaluation and Research (U.S.)
988 $a20121016
906 $0OCLC